03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
20:05 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest T cells engineered to express an anti-PSCA chimeric antigen receptor (CAR) and TGFβ-RII- and CD124-based fusion proteins could help treat pancreatic cancer. The CAR T cells...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
15:46 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells engineered to express IL-7 and CCL19 could enhance the efficacy of T cell therapies for cancer. The method involves engineering solid tumor antigen-targeting CAR T cells, dubbed proliferation-inducing and...
22:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

I-Mab to develop Genexine's HyLeukin in China

Genexine Inc. (KOSDAQ:095700) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize HyLeukin for cancer in China, Hong Kong, Macau and Taiwan. Genexine will receive an upfront payment and is eligible for development...
22:43 , Dec 22, 2017 |  BC Extra  |  Company News

I-Mab to develop Genexine's HyLeukin in China

Genexine Inc. (KOSDAQ:095700) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize HyLeukin for cancer in China, Hong Kong, Macau and Taiwan. Genexine will receive an upfront payment and is eligible for milestones...
23:20 , Dec 14, 2017 |  BC Innovations  |  Product R&D

Opening doors in PML

An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options,...
20:02 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies identified two TSLPR - CD127 fusion proteins that could help treat allergy. One fusion protein consisted of the full extracellular domain of TSLPR linked to the N-terminus of the extracellular...
21:09 , Dec 30, 2016 |  BC Week In Review  |  Company News

OSE Immunotherapeutics, Servier deal

OSE Immunotherapeutics granted Servier an option to license exclusive, worldwide rights to develop and commercialize Effi-7 . The humanized mAb targeting IL-7 receptor ( CD127 ) is in preclinical testing to treat ulcerative colitis (UC)....